文献速递遗传性与小管间质肾病

CD8+ T细胞可调节常染色体显性多囊肾病的进展

CD8+ T cells modulate autosomal dominant polycystic kidney disease progression.
PubMed 文献 · Kidney Int · 2018-09-21

本研究利用Pkd1 p.R3277C(RC)正交ADPKD小鼠模型,发现肾脏CD8+和CD4+ T细胞随疾病严重程度进行性增加,但仅CD8+ T细胞选择性活化。T细胞定位于囊性病变,且CXCL9/CXCL10趋化因子水平升高。在C57Bl/6 Pkd1RC/RC小鼠中从1至3个月免疫清除CD8+ T细胞导致ADPKD病理加重、凋亡减少和增殖增加,提示CD8+ T细胞具有肾脏保护作用。

要点

  • ADPKD小鼠肾脏CD8+和CD4+ T细胞进行性增加,与疾病严重程度相关,CD8+ T细胞选择性活化。
  • T细胞定位于囊性病变,肾脏CXCL9/CXCL10趋化因子水平升高。
  • 免疫清除CD8+ T细胞加重ADPKD病理,提示CD8+ T细胞具有保护作用。

核心结论

  • CD8+ T细胞在ADPKD进展中发挥功能性保护作用,靶向该通路可能成为ADPKD的新型治疗策略。

研究设计与样本

  • 使用正交ADPKD模型Pkd1 p.R3277C(RC)小鼠,通过流式细胞术、免疫荧光、qPCR/原位杂交及免疫清除实验研究T细胞的作用。

主要发现

  • 流式细胞术显示肾脏CD8+和CD4+ T细胞进行性增加,与疾病严重程度相关,但CD8+ T细胞选择性活化。
  • 免疫荧光显示T细胞特异性定位于囊性病变。
  • qPCR/原位杂交检测到小鼠、患者及ADPKD上皮细胞系中T细胞招募趋化因子CXCL9/CXCL10水平升高。
  • 在C57Bl/6 Pkd1RC/RC小鼠中从1至3个月免疫清除CD8+ T细胞,与IgG对照相比,导致ADPKD病理加重、凋亡减少和增殖增加。

临床怎么用

  • 针对CD8+ T细胞通路的免疫肿瘤学药物可能为ADPKD提供新的治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent inherited nephropathy. To date, therapies alleviating the disease have largely focused on targeting abnormalities in renal epithelial cell signaling. ADPKD has many hallmarks of cancer, where targeting T cells has brought novel therapeutic interventions. However, little is known about the role and therapeutic potential of T cells in ADPKD. Here, we used an orthologous ADPKD model, Pkd1 p.R3277C (RC), to begin to define the role of T cells in disease progression. Using flow cytometry, we found progressive increases in renal CD8+ and CD4+ T cells, correlative with disease severity, but with selective activation of CD8+ T cells. By immunofluorescence, T cells specifically localized to cystic lesions and increased levels of T-cell recruiting chemokines (CXCL9/CXCL10) were detected by qPCR/in situ hybridization in the kidneys of mice, patients, and ADPKD epithelial cell lines. Importantly, immunodepletion of CD8+ T cells from one to three months in C57Bl/6 Pkd1RC/RC mice resulted in worsening of ADPKD pathology, decreased apoptosis, and increased proliferation compared to IgG-control, consistent with a reno-protective role of CD8+ T cells. Thus, our studies suggest a functional role for T cells, specifically CD8+ T cells, in ADPKD progression. Hence, targeting this pathway using immune-oncology agents may represent a novel therapeutic approach for ADPKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Kleczko EK, Marsh KH, Tyler LC, et al. CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int. 2018. PMID: 30249452. doi:10.1016/j.kint.2018.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。